New therapeutic approach to vulvovaginal atrophy in patients with a history of cancer

Vulvovaginal atrophy (VVA) is one of the most common side effects of chemoradiation therapy, including an associated decrease in quality of life, particularly sexual function. The gold-standard treatment for VVA, a local estrogen therapy, is contraindicated in patients who have undergone antitumor therapy due to potential cancer risks. Today, there is no evidence base for the direct oncogenic effect of high-molecular-weight hyaluronic acid (HMW-HA) on malignant tumors of various localizations. Moreover, several researchers have demonstrated its cancer neutrality or even protective properties. Therefore, well-designed and high-quality studies are needed to evaluate not only the efficacy but also the long-term safety of HA use in patients with a history of cancer. © 2024, Dynasty Publishing House. All rights reserved.